Background: obesity is one of the major problems in the world and is associated with several comorbidities and disabling diseases e.g. cardiovascular disease, metabolic syndrome, type 2 diabetes mellitus (T2DM), infertility, certain tumor types, and GERD. Management consisted of conservative and surgical measures, conservative measures such as diet modifications physical exercise and pharmacological therapy. There was considerable evidence in the literature on the long-term positive impact of bariatric surgery as a primary therapy for the treatment of obesity and its co-morbidities.Objective: this study aimed to conclude that if gastroesophageal reflux disease develops after sleeve gastrectomy in morbidly obese patients or not. Patients and Methods: this prospective non-comparative study was conducted in Surgery Department, Al-Azhar University Hospitals in the period between October 2016 and October 2018. Study included 30 cases of morbidly obese patients (with BMI ≥ 40 Kg/m² or ≥35 Kg/m² associated with comorbidities) and they were submitted for laparoscopic sleeve gastrectomy and all of them had failed in trials of conservative management including dietary control and they are bulky eater but non-sweet eater. Results: the prevalence of gastroesophageal reflux disease (GERD) was markedly increased in morbid obese patients compared to the incidence in normal individuals, with a percentage of up to 70% of patients undergoing bariatric surgery.  SG is associated with an increase in GERD prevalence. The measured increase in GERD prevalence ranged from 2.1% to 34.9% in the analyzed literature. There was marked heterogeneity between the studies in regard to a number of factors including preoperative BMI, method of evaluating GERD, exclusion criteria, length of follow-up and operative technique. Conclusion: only in a very special group of patients with BMI between 30 and 35 and comorbidities, SG plus other antireflux procedure or hiatal hernia repair is accepted.